Welcome!

News Feed Item

Trigeminal Neuralgia Global Clinical Trials Review, H2, 2014

LONDON, Aug. 25, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Trigeminal Neuralgia Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/2312349/Trigeminal-Neuralgia-Global-Clinical-Trials-Review-H2-2014.html

Trigeminal Neuralgia Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Trigeminal Neuralgia Global Clinical Trials Review, H2, 2014" provides data on the Trigeminal Neuralgia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Trigeminal Neuralgia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Trigeminal Neuralgia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Trigeminal Neuralgia 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Clinical Trials by G7 Countries: Proportion of Trigeminal Neuralgia to Central Nervous System Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Trigeminal Neuralgia to Central Nervous System Clinical Trials 17
Clinical Trials by Phase 18
In Progress Trials by Phase 19
Clinical Trials by Trial Status 20
Clinical Trials by End Point Status 21
Unaccomplished Trials of Trigeminal Neuralgia 22
Subjects Recruited Over a Period of Time 23
Clinical Trials by Sponsor Type 24
Prominent Sponsors 25
Top Companies Participating in Trigeminal Neuralgia Therapeutics Clinical Trials 26
Prominent Drugs 27
Latest Clinical Trials News on Trigeminal Neuralgia 28
Jun 16, 2014: Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigeminal Neuralgia Study 28
Clinical Trial Profiles 29
Clinical Trial Overview of Top Companies 29
Merz Pharma GmbH & Co. KgaA 29
Clinical Trial Overview of Merz Pharma GmbH & Co. KgaA 29
Desitin Arzneimittel GmbH 30
Clinical Trial Overview of Desitin Arzneimittel GmbH 30
Convergence Pharmaceuticals Ltd. 31
Clinical Trial Overview of Convergence Pharmaceuticals Ltd. 31
Allodynic Therapeutics, LLC 32
Clinical Trial Overview of Allodynic Therapeutics, LLC 32
Clinical Trial Overview of Top Institutes / Government 33
Stanford University 33
Clinical Trial Overview of Stanford University 33
Thomas Jefferson University 34
Clinical Trial Overview of Thomas Jefferson University 34
University Health Network 35
Clinical Trial Overview of University Health Network 35
National Institute of Dental and Craniofacial Research 36
Clinical Trial Overview of National Institute of Dental and Craniofacial Research 36
Shahid Sadoughi University of Medical Sciences and Health Services 37
Clinical Trial Overview of Shahid Sadoughi University of Medical Sciences and Health Services 37
FDA Office of Orphan Products Development 38
Clinical Trial Overview of FDA Office of Orphan Products Development 38
University of Malaya 39
Clinical Trial Overview of University of Malaya 39
Riken Advanced Science Institute 40
Clinical Trial Overview of Riken Advanced Science Institute 40
University College London 41
Clinical Trial Overview of University College London 41
Capital Medical University 42
Clinical Trial Overview of Capital Medical University 42
Five Key Clinical Profiles 43
Appendix 58
Abbreviations 58
Definitions 58
Research Methodology 59
Secondary Research 59
About GlobalData 60
Contact Us 60
Disclaimer 60
Source 60

List of Tables
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials by Region, 2014* 7
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Trigeminal Neuralgia Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 10
Trigeminal Neuralgia Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Trigeminal Neuralgia Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Trigeminal Neuralgia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Proportion of Trigeminal Neuralgia to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 14
Trigeminal Neuralgia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Trigeminal Neuralgia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 16
Proportion of Trigeminal Neuralgia to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 17
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials by Phase, 2014* 18
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 19
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials by Trial Status, 2014* 20
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, by End Point Status, 2014* 21
Trigeminal Neuralgia Therapeutics, Global, Withdrawn Clinical Trials, 2014* 22
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 23
Trigeminal Neuralgia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 24
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 25
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 26
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 27
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Merz Pharma GmbH & Co. KgaA, 2014* 29
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Desitin Arzneimittel GmbH, 2014* 30
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Convergence Pharmaceuticals Ltd., 2014* 31
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Allodynic Therapeutics, LLC, 2014* 32
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014* 33
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Thomas Jefferson University, 2014* 34
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by University Health Network, 2014* 35
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Dental and Craniofacial Research, 2014* 36
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Shahid Sadoughi University of Medical Sciences and Health Services, 2014* 37
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by FDA Office of Orphan Products Development, 2014* 38
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Malaya, 2014* 39
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Riken Advanced Science Institute, 2014* 40
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by University College London, 2014* 41
Trigeminal Neuralgia Therapeutics Clinical Trials Market, Global, Clinical Trials by Capital Medical University, 2014* 42

List of Figures
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Trigeminal Neuralgia Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 10
Trigeminal Neuralgia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Trigeminal Neuralgia Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Proportion of Trigeminal Neuralgia to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 14
Trigeminal Neuralgia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Trigeminal Neuralgia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 16
Proportion of Trigeminal Neuralgia to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 17
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials by Phase (%), 2014* 18
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 19
Trigeminal Neuralgia Therapeutics, Global, Clinical Trials by Trial Status, 2014* 20
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 23
Trigeminal Neuralgia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 24
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 25
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 26
Trigeminal Neuralgia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 27
GlobalData Methodology 59


Read the full report:
Trigeminal Neuralgia Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/2312349/Trigeminal-Neuralgia-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

 

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
As data explodes in quantity, importance and from new sources, the need for managing and protecting data residing across physical, virtual, and cloud environments grow with it. Managing data includes protecting it, indexing and classifying it for true, long-term management, compliance and E-Discovery. Commvault can ensure this with a single pane of glass solution – whether in a private cloud, a Service Provider delivered public cloud or a hybrid cloud environment – across the heterogeneous enter...
Financial Technology has become a topic of intense interest throughout the cloud developer and enterprise IT communities. Accordingly, attendees at the upcoming 20th Cloud Expo at the Javits Center in New York, June 6-8, 2017, will find fresh new content in a new track called FinTech.
You have great SaaS business app ideas. You want to turn your idea quickly into a functional and engaging proof of concept. You need to be able to modify it to meet customers' needs, and you need to deliver a complete and secure SaaS application. How could you achieve all the above and yet avoid unforeseen IT requirements that add unnecessary cost and complexity? You also want your app to be responsive in any device at any time. In his session at 19th Cloud Expo, Mark Allen, General Manager of...
@DevOpsSummit taking place June 6-8, 2017 at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @DevOpsSummit at Cloud Expo New York Call for Papers is now open.
"We are a leader in the market space called network visibility solutions - it enables monitoring tools and Big Data analysis to access the data and be able to see the performance," explained Shay Morag, VP of Sales and Marketing at Niagara Networks, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor - all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
The 20th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held June 6-8, 2017, at the Javits Center in New York City, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal ...
"We are a modern development application platform and we have a suite of products that allow you to application release automation, we do version control, and we do application life cycle management," explained Flint Brenton, CEO of CollabNet, in this SYS-CON.tv interview at DevOps at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Amazon has gradually rolled out parts of its IoT offerings in the last year, but these are just the tip of the iceberg. In addition to optimizing their back-end AWS offerings, Amazon is laying the ground work to be a major force in IoT – especially in the connected home and office. Amazon is extending its reach by building on its dominant Cloud IoT platform, its Dash Button strategy, recently announced Replenishment Services, the Echo/Alexa voice recognition control platform, the 6-7 strategic...
Regulatory requirements exist to promote the controlled sharing of information, while protecting the privacy and/or security of the information. Regulations for each type of information have their own set of rules, policies, and guidelines. Cloud Service Providers (CSP) are faced with increasing demand for services at decreasing prices. Demonstrating and maintaining compliance with regulations is a nontrivial task and doing so against numerous sets of regulatory requirements can be daunting task...
Bert Loomis was a visionary. This general session will highlight how Bert Loomis and people like him inspire us to build great things with small inventions. In their general session at 19th Cloud Expo, Harold Hannon, Architect at IBM Bluemix, and Michael O'Neill, Strategic Business Development at Nvidia, discussed the accelerating pace of AI development and how IBM Cloud and NVIDIA are partnering to bring AI capabilities to "every day," on-demand. They also reviewed two "free infrastructure" pr...
"This is specifically designed to accommodate some of the needs for high availability and failover in a network managed system for the major Korean corporations," stated Thomas Masters, Managing Director at InfranicsUSA, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Unsecured IoT devices were used to launch crippling DDOS attacks in October 2016, targeting services such as Twitter, Spotify, and GitHub. Subsequent testimony to Congress about potential attacks on office buildings, schools, and hospitals raised the possibility for the IoT to harm and even kill people. What should be done? Does the government need to intervene? This panel at @ThingExpo New York brings together leading IoT and security experts to discuss this very serious topic.
CloudJumper, a Workspace as a Service (WaaS) platform innovator for agile business IT, has been recognized with the Customer Value Leadership Award for its nWorkSpace platform by Frost & Sullivan. The company was also featured in a new report(1) by the industry research firm titled, “Desktop-as-a-Service Buyer’s Guide, 2016,” which provides a comprehensive comparison of DaaS providers, including CloudJumper, Amazon, VMware, and Microsoft.
More and more brands have jumped on the IoT bandwagon. We have an excess of wearables – activity trackers, smartwatches, smart glasses and sneakers, and more that track seemingly endless datapoints. However, most consumers have no idea what “IoT” means. Creating more wearables that track data shouldn't be the aim of brands; delivering meaningful, tangible relevance to their users should be. We're in a period in which the IoT pendulum is still swinging. Initially, it swung toward "smart for smar...